Quick Answer
Dermata Therapeutics, Inc. reported Operating Income Loss of -$7.77 million for the year ending 2025.
- Dermata Therapeutics, Inc. showed an increase of +37.9% in Operating Income Loss from 2024 to 2025.
- This data is from Dermata Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on March 26, 2026.
- XBRL data for this metric is available from 2020 to 2025 (6 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Over the full 6 years of available data (2020 to 2025), Dermata Therapeutics, Inc.'s Operating Income Loss has declined by 145.0%.
- Historical annual values: Fiscal year 2025: -$7.77 million | Fiscal year 2024: -$12.51 million | Fiscal year 2023: -$8.04 million | Fiscal year 2022: -$9.67 million | Fiscal year 2021: -$7.86 million | Fiscal year 2020: -$3.17 million.
- Data sourced from SEC EDGAR public filings as of June 22, 2026.
Last verified: